Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Hensel

Showing results (11-20 of 59) with videos related to

Pageof 6
Sort By:
Clinical Lymphoma & Myeloma|October 20, 2005
Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphomaManfred Hensel, Matthias Villalobos, Martin Kornacker, et al.
Annals of Hematology|May 9, 2014
Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG)Marcus Hentrich, Christian Hoffmann, Franz Mosthaf, et al.
Virchows Archiv : an International Journal of Pathology|January 22, 2004
Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinibGunhild Mechtersheimer, Gerlinde Egerer, Manfred Hensel, et al.
European Journal of Haematology|February 14, 2004
Secondary follicular lymphoma of the bone, transformed into large cell lymphoma, in a patient with chronic lymphocytic leukaemia: an uncommon manifestation of Richter's syndromeManfred Hensel, Eike C Buss, Markus Tiemann, et al.
Leukemia Research|March 15, 2006
One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?Christina Schmitt, Alexander Grundt, Christian Buchholtz, et al.
International Journal of Cancer|September 24, 2004
Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cellsUwe Reusch, Fabrice Le Gall, Manfred Hensel, et al.
Haematologica|January 19, 2007
Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcomePeter Dreger, Michael Rieger, Bärbel Seyfarth, et al.
Stem Cells (Dayton, Ohio)|January 6, 2007
Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cellsMathias Witzens-Harig, Conny Heilmann, Manfred Hensel, et al.
International Journal of Cancer|July 13, 2002
P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell supportManfred Hensel, Andreas Schneeweiss, Hans-Peter Sinn, et al.
International Journal of Cancer|April 28, 2006
Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gammaMartin Kornacker, Gerhard Moldenhauer, Markus Herbst, et al.
Pageof 6

Showing results (11-20 of 59) with videos related to

Sort By:
Pageof 6
Clinical Lymphoma & Myeloma|October 20, 2005
Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphomaManfred Hensel, Matthias Villalobos, Martin Kornacker, et al.
Annals of Hematology|May 9, 2014
Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG)Marcus Hentrich, Christian Hoffmann, Franz Mosthaf, et al.
Virchows Archiv : an International Journal of Pathology|January 22, 2004
Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinibGunhild Mechtersheimer, Gerlinde Egerer, Manfred Hensel, et al.
European Journal of Haematology|February 14, 2004
Secondary follicular lymphoma of the bone, transformed into large cell lymphoma, in a patient with chronic lymphocytic leukaemia: an uncommon manifestation of Richter's syndromeManfred Hensel, Eike C Buss, Markus Tiemann, et al.
Leukemia Research|March 15, 2006
One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?Christina Schmitt, Alexander Grundt, Christian Buchholtz, et al.
International Journal of Cancer|September 24, 2004
Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cellsUwe Reusch, Fabrice Le Gall, Manfred Hensel, et al.
Haematologica|January 19, 2007
Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcomePeter Dreger, Michael Rieger, Bärbel Seyfarth, et al.
Stem Cells (Dayton, Ohio)|January 6, 2007
Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cellsMathias Witzens-Harig, Conny Heilmann, Manfred Hensel, et al.
International Journal of Cancer|July 13, 2002
P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell supportManfred Hensel, Andreas Schneeweiss, Hans-Peter Sinn, et al.
International Journal of Cancer|April 28, 2006
Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gammaMartin Kornacker, Gerhard Moldenhauer, Markus Herbst, et al.
Pageof 6